JP6170903B2 - 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体 - Google Patents

組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体 Download PDF

Info

Publication number
JP6170903B2
JP6170903B2 JP2014502846A JP2014502846A JP6170903B2 JP 6170903 B2 JP6170903 B2 JP 6170903B2 JP 2014502846 A JP2014502846 A JP 2014502846A JP 2014502846 A JP2014502846 A JP 2014502846A JP 6170903 B2 JP6170903 B2 JP 6170903B2
Authority
JP
Japan
Prior art keywords
tfpi
seq
fab
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014502846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511685A (ja
Inventor
ワン・ジュオジ
ジョン・マーフィー
トビアス・マルクヴァルト
ディーター・モースマイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6170903(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of JP2014511685A publication Critical patent/JP2014511685A/ja
Application granted granted Critical
Publication of JP6170903B2 publication Critical patent/JP6170903B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014502846A 2011-04-01 2012-03-30 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体 Expired - Fee Related JP6170903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
US61/471,101 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017027825A Division JP6363747B2 (ja) 2011-04-01 2017-02-17 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2014511685A JP2014511685A (ja) 2014-05-19
JP6170903B2 true JP6170903B2 (ja) 2017-07-26

Family

ID=46932389

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014502846A Expired - Fee Related JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2017027825A Expired - Fee Related JP6363747B2 (ja) 2011-04-01 2017-02-17 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017027825A Expired - Fee Related JP6363747B2 (ja) 2011-04-01 2017-02-17 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR101995302B1 (enExample)
CN (2) CN107090046A (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA201991704A3 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY190951A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039B1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG193594A1 (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018172411A (ja) * 2011-04-01 2018-11-08 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US11279771B2 (en) * 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX388251B (es) * 2015-02-25 2025-03-19 Mogam Inst Biomedical Res Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018172411A (ja) * 2011-04-01 2018-11-08 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Also Published As

Publication number Publication date
US20220041752A1 (en) 2022-02-10
CA2831907A1 (en) 2012-10-04
WO2012135671A2 (en) 2012-10-04
PH12013502039A1 (en) 2013-12-16
HK1243426A1 (zh) 2018-07-13
IL274686B (en) 2021-09-30
JP2014511685A (ja) 2014-05-19
SG193594A1 (en) 2013-10-30
CA3068997A1 (en) 2012-10-04
CL2013002811A1 (es) 2014-02-28
WO2012135671A3 (en) 2012-12-13
MX2013011218A (es) 2013-10-17
GT201300229A (es) 2014-11-13
EA201301107A1 (ru) 2014-11-28
AU2019201814A1 (en) 2019-04-04
SI2694544T1 (sl) 2019-06-28
EA034214B1 (ru) 2020-01-17
US20180194857A1 (en) 2018-07-12
CN103797030B (zh) 2017-05-31
US20190194353A1 (en) 2019-06-27
ES2722824T3 (es) 2019-08-19
EP2694544A2 (en) 2014-02-12
EA201991704A3 (ru) 2020-06-30
AU2012236296A1 (en) 2013-10-24
CN103797030A (zh) 2014-05-14
ZA201308169B (en) 2016-03-30
PH12013502039B1 (en) 2013-12-16
CU20130128A7 (es) 2014-03-26
RS58633B1 (sr) 2019-05-31
BR112013025376A2 (pt) 2017-07-25
EP2694544A4 (en) 2015-03-25
IL228633A0 (en) 2013-12-31
IL283829A (en) 2021-07-29
CR20130499A (es) 2013-10-24
JP2017113019A (ja) 2017-06-29
US20170107298A1 (en) 2017-04-20
SG10201602606UA (en) 2016-04-28
KR20190079698A (ko) 2019-07-05
EA201991704A2 (ru) 2020-03-31
IL228633B (en) 2018-03-29
IL274686A (en) 2020-06-30
JP2021019619A (ja) 2021-02-18
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
NZ615969A (en) 2016-01-29
PH12019500439A1 (en) 2020-10-12
HRP20190467T1 (hr) 2019-05-03
UA113623C2 (uk) 2017-02-27
ECSP13012913A (es) 2014-02-28
CA2831907C (en) 2020-03-24
EP2694544B1 (en) 2019-01-23
DK2694544T3 (en) 2019-04-15
HUE042706T2 (hu) 2019-07-29
PL2694544T3 (pl) 2019-07-31
PE20141149A1 (es) 2014-08-28
LT2694544T (lt) 2019-04-25
US20140294832A1 (en) 2014-10-02
PH12019500441A1 (en) 2020-10-12
IL257145A (en) 2018-03-29
CO6890074A2 (es) 2014-03-10
JP6363747B2 (ja) 2018-07-25
TR201905101T4 (tr) 2019-05-21
KR20140019428A (ko) 2014-02-14
JP2018172411A (ja) 2018-11-08
KR101995302B1 (ko) 2019-07-02
CN107090046A (zh) 2017-08-25
DOP2013000218A (es) 2013-11-15
MY165499A (en) 2018-03-27
CY1121538T1 (el) 2020-05-29
PT2694544T (pt) 2019-04-02
AU2017203105A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
JP6363747B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6684369B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202745B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK1197829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829B (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150326

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170703

R150 Certificate of patent or registration of utility model

Ref document number: 6170903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees